{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(1)"],"submitter":["Paramonova M"],"pubmed_abstract":["Graphical abstract  The title compounds were prepared from 1-[5-(4-bromophenoxy) pentyl]uracil by the introduction of N-arylacetamide moiety at the 3-position, the better approach involving the use of N-aryl-2-chloroacetamides as the reactants. Antiviral activity of the obtained compounds was estimated."],"journal":["Mendeleev Communications"],"pagination":["85-87"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7148871"],"repository":["biostudies-literature"],"pubmed_title":["Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties"],"pmcid":["PMC7148871"],"pubmed_authors":["Paramonova M","Khandazhinskaya A","Seley-Radtke K","Novikov M"],"additional_accession":[]},"is_claimable":false,"name":"Novel 1-[5-(4-bromophenoxy)pentyl]-3-(2-arylamino- 2-oxoethyl)uracils and their antiviral properties","description":"Graphical abstract  The title compounds were prepared from 1-[5-(4-bromophenoxy) pentyl]uracil by the introduction of N-arylacetamide moiety at the 3-position, the better approach involving the use of N-aryl-2-chloroacetamides as the reactants. Antiviral activity of the obtained compounds was estimated.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jan","modification":"2025-04-04T03:42:33.547Z","creation":"2020-05-22T17:00:47Z"},"accession":"S-EPMC7148871","cross_references":{}}